Scarica l'app Stockscreener
13.26
4.67%
-0.65
Dopo l'orario di chiusura:
13.34
0.08
+0.60%
Precedente Chiudi:
$13.91
Aprire:
$13.89
Volume 24 ore:
1.64M
Relative Volume:
0.66
Capitalizzazione di mercato:
$4.23B
Reddito:
$3.02B
Utile/perdita netta:
$127.93M
Rapporto P/E:
59.92
EPS:
0.2213
Flusso di cassa netto:
$225.64M
1 W Prestazione:
+3.35%
1M Prestazione:
+12.09%
6M Prestazione:
+29.49%
1 anno Prestazione:
+80.16%
Intervallo 1D:
$13.10
$13.92
Intervallo di 1 settimana:
$12.82
$13.92
Portata 52W:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.26 | 4.44B | 3.02B | 127.93M | 225.64M | 0.2213 |
TAK
Takeda Pharmaceutical Co Adr
|
17.55 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.72 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.68 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.02 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
573.44 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | UBS | Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
Amneal reports positive interim data for Parkinson’s drug Crexont - Investing.com
After a RYTARY switch, Parkinson's patients gained 3 'Good On' hours - Stock Titan
Amneal Pharmaceuticals stock (US03168L1052): Why Google Discover changes matter more now - AD HOC NEWS
Amneal rated Buy in new research coverage at UBS as growth pipeline expands (AMRX:NASDAQ) - Seeking Alpha
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
Healthcare Stocks Rise as Strait Reopening Cuts Costs | 2026 Market UpdateNews and Statistics - IndexBox
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded to "Strong-Buy" at UBS Group - MarketBeat
UBS initiates coverage of Amneal Pharmaceuticals (AMRX) with buy recommendation - MSN
Market movers: Netflix, American Airlines, United Airlines, Amneal Pharmaceuticals... - Proactive financial news
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma - Yahoo! Finance Canada
UBS initiates Amneal Pharmaceuticals stock with buy rating at $19 - Investing.com
Amneal denied summary judgment against US states’ antitrust case over Phenytoin - MLex
Amneal Trims But Can't Nix AGs' Drug Price-Fixing Suit - Law360
Judge Dismisses Benzene Suit For Failure To State A Claim But Grants Leave To Amend - Mealey's
92,010 Shares in Amneal Pharmaceuticals, Inc. $AMRX Purchased by Tudor Investment Corp ET AL - MarketBeat
Is AMRX stock undervalued? Sales multiple, target, upside - MSN
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. - Yahoo Finance
Amneal launches generic bimatoprost 0.01% to US market - Eyes On Eyecare
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Significant Decrease in Short Interest - MarketBeat
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced the official launch of Albuterol Sulfate and Beclomethasone Dipropionate HFA inhalation aerosols in the U.S. market. - Bitget
Institution Moves: Is Amneal Pharmaceuticals Inc a strong candidate for buy and hold2026 Price Momentum & Low Risk High Reward Ideas - baoquankhu1.vn
Aug Fed Impact: Is Amneal Pharmaceuticals Inc in a long term uptrend2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Should Amneal’s New Generic Glaucoma Launch Shape How AMRX Investors View Its Specialty Strategy? - Sahm
Fund Flows: Is Amneal Pharmaceuticals Inc forming a double bottomEarnings Overview Summary & Fast Momentum Entry Tips - baoquankhu1.vn
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook - qz.com
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing - qz.com
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside - qz.com
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
AMRX: 3 Key Factors Fueling Amneal's Projections for 2026 - Bitget
Here's the way AMRX is leveraging the demand for GLP-1 via its manufacturing operations - Bitget
Why Amneal Pharmaceuticals (AMRX) Stands Out as a Leading Long-Term Growth Stock - Bitget
FOCUS-Patients scramble to find estrogen patches as shortage worsens after US FDA champions use - Sahm
Is It Time To Reassess Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Share Price Run? - Sahm
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Launching Its New Glaucoma Generic - Yahoo Finance
FDA sends latest Untitled Letters to Amneal, BioCorRx over brochures, websites - Medical Marketing and Media
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% - Bitget
Amneal rolls out generic glaucoma eye drop in a $719M U.S. market - Stock Titan
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.58%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):